Abstract:Human and murine brains retain discrete populations of micro RNA (miRNA) species that support homeostatic brain gene expression functions, and specific miRNA abundances are significantly and progressively altered in neurological disorders such as Alzheimer disease (AD), prion disease (PrD) and transgenic AD (Tg-AD) murine models when compared to age-matched controls. The innate-immune and pro-inflammatory, NF-kB-regulated 22-nucleotide single-stranded miRNA-146a is significantly up-regulated in parallel with the development of AD and PrD and with the onset of amyloidogenesis in several Tg-AD murine models. Here for the first time we provide evidence of significant up-regulation of miRNA-146a in amyloid-and-cytokine-stressed human neuronal-glial cells in primary co-culture and in the brains of 5xFAD mice [Tg(APPSwFlLon,PSEN1*M146L *L286V)6799Vas] which bear 5 (APP695+PSEN1) mutations that strongly drive the generation of Aβ42 peptides. AAV-miRNA vectors, microRNA analysis, 5xFAD Tg-AD models, RNA sequencing, RT-PCR, LED-Northern, microfluidic and bioinformatics technologies. Using stereotactic bilateral hippocampal injection of a scrambled AAV-miRNA-146a vector into 5xFAD brains as a baseline, selective AAV-miRNA-146a sponging vectors delivered into the hippocampus of 5xFAD mice exhibited (i) decreases in host miRNA-146a expression; (ii) increases in expression of the complement control glycoprotein complement factor H (CFH); (iii) decreases in BACE1, sAPPβsw and the generation of Aβ42 peptides; (iv) decreases in the expression of inflammatory and microglial markers including cyclooxygenase-2 (COX-2), glial fibrillary acidic protein (GFAP) and Iba1; (v) increased expression of the synaptic markers SYN1 and NR2B; and (vi) a significant improvement in cognitive performance in maze tests (NOR and Y-maze). Collectively, the results suggest that the implementation of a novel therapeutic strategy involving the sponging of miRNA-146a and related pro-inflammatory, pathogenic miRNAs may be useful in the effective treatment of AD and other progressive, age-related neurological disorders. Support: Research on miRNA in the Lukiw laboratory involving the innate-immune response in AD, AMD and in other forms of neurological or retinal disease, amyloidogenesis and neuro-inflammation was supported through an unrestricted grant to the LSU Eye Center from Research to Prevent Blindness (RPB); the Louisiana Biotechnology Research Network (LBRN) and grants from the NIH NEI and NIA.

MiR-431 attenuates synaptic plasticity and memory deficits in APPswe/PS1dE9 mice

Down‐regulated Expression of Microrna‐338‐5p Contributes to Neuropathology in Alzheimer's Disease

MicroRNA-139 Modulates Alzheimer's-associated Pathogenesis in SAMP8 Mice by Targeting Cannabinoid Receptor Type 2.

miR-429-3p mediates memory decline by targeting MKP-1 to reduce surface GluA1-containing AMPA receptors in a mouse model of Alzheimer's disease

O3‐01‐05: MIR‐204 ATTENUATES MEMORY DEFICITS IN A MOUSE MODEL OF ALZHEIMER'S DISEASE

miR-204-3p/Nox4 Mediates Memory Deficits in a Mouse Model of Alzheimer's Disease

miR-204-3p/Nox4 Mediates Memory Deficits in a Mouse Model of Alzheimer's Disease.

Genome-wide Analysis of Mirna Signature in the APPswe/PS1ΔE9 Mouse Model of Alzheimer's Disease.

MicroRNA‐134‐5p inhibition rescues long‐term plasticity and synaptic tagging/capture in an Aβ(1–42)‐induced model of Alzheimer’s disease

Mir-124 Downregulates Bace 1 and Alters Autophagy in App/Ps1 Transgenic Mice

MiR-191-5p alleviates microglial cell injury by targeting Map3k12 (mitogen-activated protein kinase kinase kinase 12) to inhibit the MAPK (mitogen-activated protein kinase) signaling pathway in Alzheimer’s disease

A Novel MicroRNA-124/PTPN1 Signal Pathway Mediates Synaptic and Memory Deficits in Alzheimer's Disease

miR-132 regulates the expression of synaptic proteins in APP/PS1 transgenic mice through C1q

Decreased miR-451a in cerebrospinal fluid, a marker for both cognitive impairment and depressive symptoms in Alzheimer's disease.

MicroRNA-338-5p Alleviates Neuronal Apoptosis Via Directly Targeting BCL2L11 in APP/PS1 Mice

miR-146a-5p Modulates Adult Hippocampal Neurogenesis Deficits Through Klf4/p-Stat3 Signaling in APP/PS1 Mice

miR-3940-5p reduces amyloid β production via selectively targeting PSEN1

Elevated Levels of miR-144-3p Induce Cholinergic Degeneration by Impairing the Maturation of NGF in Alzheimer’s Disease

microRNA‐425 loss mediates amyloid plaque microenvironment heterogeneity and promotes neurodegenerative pathologies

miR-30a-5p induces Aβ production via inhibiting the nonamyloidogenic pathway in Alzheimer’s disease

Sponging of mirna-146a using aav-anti-mirna-146a-vectors mediates synaptic and amyloidogenic neuropathology and cognitive deficits in a 5xfad murine model of alzheimer’s disease